Investing.com - Myriad Genetics (NASDAQ: MYGN) reported third quarter EPS of $-0.01, $0.09 better than the analyst estimate of $-0.10. Revenue for the quarter came in at $202.2M versus the consensus estimate of $193.51M.
Myriad Genetics's stock price closed at $19.78. It is down -10.09% in the last 3 months and up 7.97% in the last 12 months.
Myriad Genetics saw 1 positive EPS revisions and 9 negative EPS revisions in the last 90 days. See Myriad Genetics's stock price’s past reactions to earnings here.
According to InvestingPro, Myriad Genetics's Financial Health score is "fair performance".
Check out Myriad Genetics's recent earnings performance, and Myriad Genetics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar